A Compliance-Oriented Evaluation of Manual Versus AI-Driven Approaches a Scientific and Regulatory Perspective for Quality and Safety Professionals
Abstract
Medical literature monitoring is a core regulatory requirement for pharmacovigilance systems worldwide. Traditional manual monitoring workflows are increasingly challenged by expanding publication volumes, global language diversity, and the demand for real-time signal detection. This paper evaluates the limitations of manual literature surveillance and presents an AI-driven automated alternative designed to meet modern regulatory, quality, and inspection expectations. Operational efficiency, data integrity, audit traceability, and global literature coverage are assessed from a scientific and compliance perspective.
Regulatory Context and Requirements
Global regulatory authorities require Marketing Authorisation Holders (MAHs) to maintain continuous surveillance of scientific literature for potential safety information. This obligation is defined in:
- EU Good Pharmacovigilance Practices (GVP)
- U.S. Food and Drug Administration post-marketing safety reporting regulations
- International Council for Harmonisation guidelines (ICH)
- European Medicines Agency inspection frameworks
Key regulatory expectations include:
- Systematic surveillance of global and local literature
- Timely identification of ICSRs from literature
- Detection of potential safety signals
- Documentation of search strategies and outcomes
- Duplicate control
- Full audit trail and inspection readiness
Failure to meet these expectations may result in regulatory findings, delayed signal identification, or enforcement actions.
Scientific Limitations of Manual Literature Monitoring
Search Sensitivity and Reproducibility
Manual query strategies vary substantially between reviewers, databases, and vendors. This limits:
- Reproducibility of search results
- Validation of historical surveillance
- Assurance of full retrieval sensitivity
Subtle changes in indexing, synonyms, or spelling across databases further reduce completeness.
Data Integrity and Transcription Risk
Manual workflows require:
- Copying bibliographic data into Excel or Word
- Manual tagging of relevance
- Manual handling of duplicates
These steps introduce:
- Transcription errors
- Inconsistent metadata
- Version control issues
- Weak data lineage
From a quality-systems perspective, this undermines ALCOA+ data-integrity principles.
Reviewer Bias and Cognitive Load
Manual abstract screening is susceptible to:
- Fatigue-induced classification error
- Inconsistent interpretation of reportability
- Variable thresholds for seriousness assessment
- Inconsistent identification of special situations
These factors are well-recognised contributors to signal-detection delay.
Local Literature Under-Surveillance
Many organisations:
- Do not consistently monitor non-indexed national journals
- Lack systematic translation workflows
- Rely on ad-hoc local affiliates
This creates regulatory exposure, particularly during EMA or FDA inspections, where proof of local literature completeness is increasingly requested.
AI-Driven Automated Literature Monitoring: Scientific Principles
The Biologit Platform applies validated artificial intelligence algorithms to automate three core pharmacovigilance surveillance functions:
- Literature acquisition
- Duplicate control
- Safety-relevant classification
Data Sources and Global Coverage
The system simultaneously surveys:
- Indexed biomedical databases
- Open-access academic repositories
- Regional and non-indexed national journals
- Continuous ingestion of new publications
Non-English content is processed through automated language detection and translation, enabling uniform global safety assessment.
Automated Query Generation and Execution
Unlike manual Boolean strategies, automated surveillance uses:
- Drug-name ontologies
- INN/brand/synonym mapping
- Spelling variants
- Contextual term expansion
This standardises retrieval sensitivity and removes operator variability.
AI-Based Abstract Classification Framework
Each publication is automatically classified into PV-relevant categories including:
- Suspected adverse events
- Individual patient case reports
- Aggregated safety data
- Special populations and special situations
- Non-clinical research exclusions
This provides structured safety triage before any human review occurs.
Compliance, Validation, and Inspection Readiness
Audit Trail and Traceability
Each record includes:
- Source journal traceability
- Date/time of retrieval
- Classification history
- User decisions and modifications
- Export and reporting lineage
This provides end-to-end traceability aligned with:
- GVP Module I Quality Systems
- Computerised System Validation (CSV) expectations
- Data-integrity inspection requirements
Duplicate Control
Automated duplicate detection eliminates:
- Cross-database duplication
- Longitudinal re-review of recurring publications
- Manual duplicate reconciliation error
This directly improves surveillance efficiency and prevents false safety inflation.
Operational Performance Evaluation
Using Docetaxel as a reference product:
Figure 1: Operational Performance Evaluation using Docetaxel as a reference product
This reduction reflects:
- Elimination of manual data ingestion
- Removal of duplicate handling
- AI-assisted abstract triage
- Batch exclusion of non-relevant data
Impact on Signal Detection and Risk Management
From a pharmacovigilance science perspective, automated monitoring enables:
- Earlier detection of emerging safety patterns
- Increased sensitivity across global data sources
- More consistent classification across programs
- Improved time-to-signal hypothesis generation
- Enhanced cumulative safety data completeness
This strengthens:
- PSUR/PBRER robustness
- RMP signal evaluation
- Continuous benefit–risk assessment
Quality-System and Business Continuity Advantages
Automation provides:
- Reduced dependency on individual reviewer availability
- Standardised surveillance across vendors and affiliates
- Scalable operations without linear headcount growth
- Improved vendor qualification and oversight
- Stronger business-continuity resilience
Conclusion
Manual literature monitoring, while historically foundational, no longer satisfies the combined demands of:
- Global regulatory compliance
- Expanding publication volumes
- Local-language safety surveillance
- Inspection-grade data integrity
- Resource sustainability
AI-driven automation represents a scientifically robust and regulator-aligned evolution of pharmacovigilance surveillance. By standardising retrieval sensitivity, strengthening auditability, and reducing signal latency, the Biologit Platform supports both scientific excellence and regulatory defensibility in modern safety systems.
About Biologit
Biologit is the first and only technology company dedicated to global and local literature monitoring for pharmacovigilance (PV). Our AI-powered, GxP-validated platform supports pharmaceutical companies and CROs in meeting regulatory demands efficiently, transparently, and at scale.
Built for the unique needs of PV teams, Biologit replaces fragmented systems with a single, intuitive platform that handles all relevant sources — from global open-access databases to regional, subscription-only, and print publications. With up to 70% efficiency gains, it frees PV professionals to focus on strategic safety decisions.
Founded by PV expert Dr Nicole Baker and engineering leader Bruno Ohana, Biologit serves many of the world’s top 25 pharma companies across 170 countries.
